News Release - AHK Korea
News Release - AHK Korea
News Release - AHK Korea
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>News</strong> <strong>Release</strong><br />
May 19, 2010<br />
Merck Ltd. <strong>Korea</strong><br />
Merck Advanced Technologies Ltd.<br />
Haesung-2-Bldg. 15 th Floor<br />
942-10, Daechi-2-dong, Gangnam-gu<br />
Seoul 135-725, <strong>Korea</strong><br />
Phone +82 (02) 2185-3800<br />
Fax +82 (02) 2185-3900<br />
http://www.merck.co.kr<br />
Your Contact<br />
Corporate Communication<br />
Soo-Kyung Jeon (2185-3919 / 010-4746-3919)<br />
Kyung-Jin Hahn (2185-3838 / 010-8763-3838)<br />
“ Merck Young Scientist Award for Bioscience” Winner Announced<br />
• Dr. Young-Duk Yang(Seoul National University) wins first place; Dr. Seo-Gang<br />
Hyun(Seoul National University) places second<br />
• Award ceremony held during the international conference of KSBMB<br />
Seoul, May 19, 2009 – Merck Limited <strong>Korea</strong> (President: Mr. Juergen Koenig), the <strong>Korea</strong>n<br />
affiliate of Germany-based Merck KGaA, announced the first winners of its “‘Merck Young<br />
Scientist Award for Bioscience.“ The award ceremony and lectures were held May 18 during<br />
the international conference of KSBMB (the <strong>Korea</strong>n Society of Biochemistry and Molecular<br />
Biology).<br />
In order to discover and encourage young and able talents, the Merck Young Scientist Award<br />
was first established in the USA in 2007 and is currently given out in countries such as<br />
Australia, Japan, Malaysia, and the Philippines etc. Merck <strong>Korea</strong> has decided to run and<br />
support the award jointly with Merck KGaA and KSBMB, and to continue the selection on an<br />
annual basis.<br />
The first-place Merck Young Scientist Award for 2010 went to Young-Duk Yang, a Ph.D.<br />
candidate in the Oh U Lab, College of Medicine at Seoul National University. The entry is<br />
“TMEM16A confers receptor – activated calcium-dependent chloride conductance”.<br />
“ I would like to express my thanks to Merck <strong>Korea</strong> and KSBMB for their support and<br />
encouragement for my research. And I will strive to achieve further developments in the field<br />
Page 1 of 3
<strong>News</strong> <strong>Release</strong><br />
of bioscience,” Dr. Young-Duk Yang commented after the ceremony. In addition, the second-<br />
place winner, Dr. Seo-Gang Hyun in Department of Biochemistry & Molecular Biology, Seoul<br />
national University, said that he will persevere in her efforts to be a better scientist and<br />
expressed his special thanks to professors and researchers in the same lab.<br />
The first winner’s paper details the Calcium-activated Chloride Channel(CaCC). CaCC is<br />
world’s first cloned by ion channel protein candidates using Bioinformatics. And it was named<br />
as Anoctamin1(ANO1).<br />
The purpose of the award is to select scientists with excellent research performance in the<br />
life science area, which is regarded as a future growth engine, and to encourage young<br />
scientists to focus on their research and bring along future star researchers who will play a<br />
pivotal role in the development of the field. With the award, Merck will further consolidate its<br />
position as an innovative partner to the life science field in <strong>Korea</strong>.<br />
About Merck <strong>Korea</strong><br />
Merck Ltd. <strong>Korea</strong>, registered in 1989, and Merck Advanced Technologies Ltd., established in 2002, are the Merck<br />
companies in <strong>Korea</strong> and operate in pharmaceutical and the chemical industries of Liquid Crystals, Performance &<br />
Life Science Chemicals such as Pigments, Life Science products and Analytics. In 1999, Merck <strong>Korea</strong> set up its<br />
<strong>Korea</strong>n pharmaceutical operation. This was integrated with Serono <strong>Korea</strong> after Merck KGaA’s acquisition of<br />
Serono S.A. in 2007. After organizing ourselves, Merck <strong>Korea</strong> set to introduce new products step by step and will<br />
continue in the future. In addition, Merck has been increasing the number of clinical trials in <strong>Korea</strong>. Merck has a<br />
strong relation with R&D in <strong>Korea</strong>, not only in the medical area but also in the chemical field. In 2008 Merck KGaA<br />
decided to invest EUR 11 million in a new Advanced Technology Center (ATC) to improve Merck’s R&D and<br />
manufacturing capacities by providing high quality products in the rapidly increasing display market, while<br />
continuing to support customers by allowing them to achieve business success through advanced technologies<br />
and close relationship in a rapidly changing display technology Also, this investment reconfirms Merck’s<br />
commitment and responsibility to contribute innovative solutions for the future success of the <strong>Korea</strong>n display<br />
industry. And its inauguration ceremony is held in May 2010.<br />
.<br />
About Merck<br />
Merck is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a history that<br />
began in 1668, and a future shaped by approximately 33,600 employees in 64 countries. Its success is<br />
characterized by innovations from entrepreneurial employees. Merck's operating activities come under the<br />
umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders<br />
Page 2 of 3
<strong>News</strong> <strong>Release</strong><br />
own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been<br />
an independent company ever since.<br />
Page 3 of 3
Change language